PMID- 35511414
OWN - NLM
STAT- MEDLINE
DCOM- 20220517
LR  - 20220603
IS  - 1179-1918 (Electronic)
IS  - 1173-2563 (Linking)
VI  - 42
IP  - 5
DP  - 2022 May
TI  - Combination of Bevacizumab and Osimertinib in Patients with EGFR T790M-Mutated 
      Non-small Cell Lung Cancer.
PG  - 459-464
LID - 10.1007/s40261-022-01145-7 [doi]
AB  - BACKGROUND: Osimertinib may improve the prognosis of patients with epidermal 
      growth factor receptor (EGFR) T790M-mutated non-small cell lung cancer (NSCLC); 
      however, to date, the efficacy and safety of osimertinib plus bevacizumab have 
      not been elucidated. OBJECTIVE: We aimed to investigate the additional effect of 
      bevacizumab plus osimertinib compared with osimertinib alone in NSCLC patients 
      with EGFR T790M mutation. METHODS: In this study, 32 patients received 
      osimertinib alone, while 20 patients received osimertinib plus bevacizumab. The 
      median follow-up was 12 months. Overall survival (OS) and progression-free 
      survival (PFS) were estimated and adverse events (AEs) were compared. RESULTS: 
      The overall response rate (ORR) was higher in the combination group than in the 
      osimertinib-alone group (70.0% vs. 43.8%), and the OS (12.8% +/- 7.7% vs. 
      45.4% +/- 12.0%; p = 0.038) and PFS (37.3% +/- 11.9% vs. 55.3% +/- 14.3%; p = 0.045) 
      were also significantly improved in patients who underwent osimertinib plus 
      bevacizumab. Furthermore, the incidence of hypertension was significantly higher 
      in the combination arm when compared with osimertinib alone (p = 0.003), and the 
      number of other AEs were not significantly increased by adding bevacizumab (all 
      p > 0.05). CONCLUSION: Concomitant use of bevacizumab and osimertinib in NSCLC 
      patients with EGFR T790M mutation may have potential therapeutic effect than 
      osimertinib alone. Further studies with a larger number of patients are warranted 
      to confirm results of this study.
CI  - (c) 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
FAU - Liu, Sha
AU  - Liu S
AD  - Department of Radiotherapy, The First Affiliated Hospital of Hainan Medical 
      University, Haikou, 570216, China.
FAU - Pan, Tao
AU  - Pan T
AD  - Department of Radiotherapy, The First Affiliated Hospital of Hainan Medical 
      University, Haikou, 570216, China.
FAU - Wang, Ming-Kun
AU  - Wang MK
AD  - Department of Radiotherapy, The First Affiliated Hospital of Hainan Medical 
      University, Haikou, 570216, China.
FAU - Wang, Jie
AU  - Wang J
AD  - Department of Respiratory Diseases, The First Affiliated Hospital of Hainan 
      Medical University, Haikou, 570216, China.
FAU - Zhang, Shuang
AU  - Zhang S
AD  - Department of Radiotherapy, The First Affiliated Hospital of Hainan Medical 
      University, Haikou, 570216, China.
FAU - Zhou, Ping
AU  - Zhou P
AD  - Department of Radiotherapy, The First Affiliated Hospital of Hainan Medical 
      University, Haikou, 570216, China. ping.zhou@hainmc.edu.cn.
LA  - eng
GR  - 19A200036/the Scientific Research Project of Health and Family Planning Industry 
      in Hainan Province, China/
PT  - Journal Article
DEP - 20220505
PL  - New Zealand
TA  - Clin Drug Investig
JT  - Clinical drug investigation
JID - 9504817
RN  - 0 (Acrylamides)
RN  - 0 (Aniline Compounds)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - 3C06JJ0Z2O (osimertinib)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Acrylamides
MH  - Aniline Compounds/adverse effects
MH  - Bevacizumab/adverse effects
MH  - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics
MH  - ErbB Receptors/genetics
MH  - Humans
MH  - *Lung Neoplasms/drug therapy/genetics
MH  - Mutation
MH  - Protein Kinase Inhibitors/adverse effects
EDAT- 2022/05/06 06:00
MHDA- 2022/05/18 06:00
CRDT- 2022/05/05 12:04
PHST- 2022/03/22 00:00 [accepted]
PHST- 2022/05/06 06:00 [pubmed]
PHST- 2022/05/18 06:00 [medline]
PHST- 2022/05/05 12:04 [entrez]
AID - 10.1007/s40261-022-01145-7 [pii]
AID - 10.1007/s40261-022-01145-7 [doi]
PST - ppublish
SO  - Clin Drug Investig. 2022 May;42(5):459-464. doi: 10.1007/s40261-022-01145-7. Epub 
      2022 May 5.